Actionable news
0
All posts from Actionable news
Actionable news in AFMD: AFFIMED N.V.,

Affimed to Present Data on Potency of NK- and T-cell EGFRvIII TandAbs at SITC

HEIDELBERG, Germany, Oct. 6, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (AFMD), a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, today announced that the Company's abstract has been chosen for a poster presentation at the 30th annual Society for Immunotherapy of Cancer (SITC) conference, being held November 4-8 in National Harbor, Maryland. This will be the first publication of data on the Company's proprietary NK- and T-cell TandAbs generated against EGFRvIII.

Poster information

Poster Number: 231

Title: "EGFRvIII TandAbs are specific and highly potent drug candidates for the treatment of solid tumors"

Date: Thursday, Nov 5, 6:00 p.m. -- 7:30 p.m. & Friday, Nov 6, 12:30 p.m. -- 2:00 p.m.

About EGFRvIII

The Epidermal Growth Factor Receptor variant III, or EGFRvIII, has been shown to be a highly specific marker for a portion of certain solid tumors including glioblastoma, prostate cancer and head and neck cancer. Based on current research, EGFRvIII is not expressed by healthy tissues, which makes it a unique target for a highly potent cancer immunotherapy such as Affimed's T-cell TandAb(R), AFM21.

About NK-Cell TandAbs, T-Cell TandAbs and Trispecific Abs

Affimed develops TandAbs and Trispecific Abs to substantially increase the efficacy, specificity and/or extend the therapeutic window of current therapeutics. TandAbs and Trispecific Abs are a new generation of proprietary, tumor-cell engaging antibodies with a tetravalent architecture characterized by four binding domains. These tetravalent molecules bind to tumor and immune cells with...


More